In oral solid dosage form development routes using the (1R,2R)-1,2-cyclohexanedimethanol pharma grade material as a chiral linker, the material is charged at 1.00–1.05 molar equivalents relative to the carboxyl-bearing drug substance intermediate. The reaction system is kept anhydrous in a glass-lined multi-purpose reactor, and residual water is controlled below 0.05% w/w by azeotropic distillation before coupling. Compliance obligations for this route include ICH Q7 for active pharmaceutical ingredient good manufacturing practice, ICH Q3C(R8) for residual solvent control, and USP <467> for verification of residual solvent levels in the isolated intermediate. The downstream process involves low-temperature activation with an acid chloride or carbodiimide at −10 to 5 °C under nitrogen, followed by aqueous bicarbonate washing, vacuum distillation, and recrystallization from methyl tert-butyl ether/n-heptane until residual unreacted diol is below 0.1% w/w. The purified prodrug intermediate is then roller-compacted with microcrystalline cellulose, croscarmellose sodium, and colloidal silicon dioxide, compressed into immediate-release film-coated tablets, or filled into HPMC/hard gelatin capsules. Terminal product types for this route are immediate-release film-coated tablets and hard gelatin/HPMC capsules intended for oral administration. The main process bottleneck observed at pilot scale is exothermic accumulation during condensing-agent addition; the dosing rate is therefore set to maintain internal temperature below 5 °C, and the condenser is rated for −20 °C to capture volatiles. Because the diol is consumed during drug substance synthesis, residual unreacted material is controlled as a process impurity in the final API specification under ICH Q3A principles.

What Limits Water Content and Cake Elegance in Lyophilized Injectable Prodrug Intermediates?

Injectable-grade development routes use the diol at a stricter charge of 0.95–1.00 molar equivalents relative to the activated carboxyl-bearing intermediate, because residual free hydroxyl can retain water and compromise lyophilized cake structure. The route is controlled under ICH Q7, ICH Q3D(R2) elemental impurity limits, and USP <788> particulate matter in injections, with subvisible particulates assessed after reconstitution. The downstream process includes coupling in anhydrous tetrahydrofuran under nitrogen, purification by preparative C18 HPLC, solvent exchange into tert-butyl alcohol/water, and sterile filtration through a 0.22 µm PES membrane before lyophilization. The lyophilization cycle includes an annealing segment at −15 °C for 2–4 h, primary drying below −40 °C shelf set point with chamber pressure at 10–16 Pa, and secondary drying at 25–35 °C for 8–24 h until cake moisture is ≤0.5% w/w by USP <921> Karl Fischer. Terminal product types are lyophilized powders for injection in glass vials, reconstituted to clear injectable solutions meeting USP <785> osmolality specifications if required. At production scale, freeze-dryer shelf mapping and corner-vial thermocouples are required because pore structure and reconstitution time are sensitive to annealing temperature drift of ±2 °C. Residual diol in the final API is controlled below 0.15% w/w as a process impurity. The final injectable product must meet USP <790> visible particulate limits and USP <85> bacterial endotoxin specifications.

Hot-Melt Extruded Amorphous Solid Dispersions Shift Glass Transition and Drive Torque at Low Diol Loadings

In non-aqueous solid dispersion screening for BCS II active pharmaceutical ingredients, the diol is evaluated as a low molecular weight co-former/plasticizer at 2–8% w/w relative to the combined polymer and API mass. The addition ratio is not extrapolated linearly beyond 10% w/w without differential scanning calorimetry data, because phase separation and surface tack increase downstream milling burden. Process equipment includes a co-rotating twin-screw extruder with L/D 40:1, screw diameter 16–27 mm, and barrel zones set between 120–160 °C depending on the selected polymer. Screw speed is maintained at 100–300 rpm, and die pressure is monitored in the 10–50 bar range; a torque drop below 10% of the gearbox rated torque indicates over-lubrication or feed instability, while torque spikes above 70% can signal melt solidification and require increasing barrel temperature by 5 °C increments. The extrudate is air-quenched on a conveyor, milled through a 500 µm screen, blended with extragranular crospovidone and magnesium stearate, and compressed into tablets or filled into capsules. Dissolution testing is performed according to USP <711>, and content uniformity according to USP <905>. Terminal product types are amorphous solid dispersion tablets and hard capsules. Published data for this specific diol in commercial hot-melt extrusion formulations is limited; therefore, a technical-run DSC at heating rate 10 °C/min and a pilot-scale torque curve are required before lock-in of the barrel temperature profile.

When granule-based multiparticulate oral products require a low-melting binder, the diol is employed at 3–6% w/w of the dry powder charge. The process uses a high-shear granulator with a jacketed bowl preheated to 45–50 °C, and the molten diol is introduced through a heated two-fluid nozzle at 0.5–2.0 mL/min per kg of powder. End point is determined by impeller power consumption, not by fixed granulation time; a rapid increase above 15% baseline power after melt addition indicates optimal distribution, while further liquid addition can create oversized lumps above 2000 µm. The wet granules are discharged, sieved through 1000–2000 µm screens, and dried at 30–35 °C for 1–2 h in a fluid-bed dryer with inlet dew point below 5 °C to prevent binder migration. Terminal product types are granules in stick packs or sachets, and granules filled into hard capsules. Compliance includes ICH Q3C(R8) for residual solvent, USP <711> dissolution, and USP <905> content uniformity. This route is considered shallow-data in comparison to lyophilization or hot-melt extrusion; published data for this specific diol as a commercial melt binder is limited, and scale-up from 10 L bowl to production requires re-mapping the impeller power curve.

Injectable Depot Polyester Microsphere Preparation with Chiral Diol Monomer Feeds

Injectable sustained-release microsphere development uses the (1R,2R)-diol as a chiral diol monomer in polyester synthesis at 5–25% mol of total diol feed in a condensation polymerization with aliphatic diacids and poly(ethylene glycol) blocks. The polymerization is conducted in a 50–100 L glass-lined reactor at 180–220 °C under vacuum below 10 mbar with a distillate cold trap, using titanium(IV) isopropoxide at 0.05–0.2% w/w as catalyst. Intrinsic viscosity is monitored by ISO 1628-1:2021 or equivalent; polymer with IV 0.3–0.7 dL/g is selected for microsphere formation. The downstream process includes oil-in-water solvent evaporation with poly(vinyl alcohol) as emulsion stabilizer, dichloromethane evaporation at 25–35 °C under reduced pressure, and sieving to 20–100 µm microspheres. Terminal product type is a sterile injectable suspension of polymer microspheres after aseptic manufacturing or gamma irradiation with dose mapping. Compliance includes ISO 10993-1:2018 biocompatibility evaluation, ICH Q3D(R2), USP <788>, and USP <790>. A key operational boundary is that terminal heat sterilization is unsuitable when the polyester glass transition temperature falls below 45 °C; aseptic processing is then required. Polymer color shift and molecular weight drift occur if the vacuum line drops below 5 mbar; overhead stirrer torque and acid value titration are therefore recorded every 30 min during polycondensation.

When Parenteral Small-Molecule Oncology Synthesis Requires a Chiral Diol Building Block

When the (1R,2R) diol is used as a chiral building block for parenteral small-molecule oncology intermediate synthesis, the charge ratio is fixed at 1.0–1.1 molar equivalents relative to the electrophilic coupling partner in dry tetrahydrofuran. The reaction is performed in a 50–100 L glass-lined reactor at −5 to 5 °C under nitrogen, with addition of diisopropylcarbodiimide or an equivalent condensing agent over 2–4 h to control exotherm. After aqueous work-up, the crude intermediate is purified by preparative C18 HPLC using acetonitrile and 0.1% trifluoroacetic acid mobile phases; product-containing fractions are pooled, concentrated, and lyophilized. The final isolated API is then used to prepare sterile injectable solution or lyophilized cake dosage forms by aseptic filling into glass vials. Compliance includes ICH Q7, ICH Q3D(R2), USP <788>, USP <790>, and 21 CFR 211.194 for laboratory records. The terminal product types are sterile injectable solution vials and lyophilized cakes for reconstitution. A known operational boundary is residual trifluoroacetic acid retention on the API; if the final lyophilization step is shortened below 24 h, residual solvent levels may exceed ICH Q3C(R8) limits unless a secondary vacuum drying step is inserted. Unreacted diol is controlled in the final API specification at ≤0.15% w/w.